← Leaderboards
Carlos Castro-Gonzalez
Leuko Labs, Inc.
$5,762,701
Attributed
$5,762,701
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,762,701 · 2
By mechanism
R44$5,493,782 · 1
R43$268,919 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Interview”
- Kristen Jacklin · University Of Minnesota$11,691,156
- Thomas J Bell · National Disease Research Interchange$8,698,122
- Lewei Allison Lin · Veterans Health Administration$8,505,773
- Miriam Komaromy · Rand Corporation$7,862,333
- Jonathan Flint · University Of California Los Angeles$7,503,023
- Dawn C Ward · University Of California Los Angeles$7,282,377
Research focus
InterviewInfectionFeverGrowthHospitalsIncidenceAlgorithmsDevicesColony-Stimulating FactorsFingersCostHospitalizationBlood CapillariesImmunosuppressionBlood SpecimenCancer PatientClinicClinical ResearchCellsAccident And Emergency DepartmentChemotherapyFightingClassificationLeukocytes
Grant awards (6)
Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$1,802,488
R44 · FY2025 · CA · contact PI
Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$1,702,979
R44 · FY2024 · CA · contact PI
Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$806,002
R44 · FY2021 · CA · contact PI
Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$1,182,313
R44 · FY2020 · CA · contact PI
Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$55,000
R43 · FY2020 · CA · contact PI
Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer$213,919
R43 · FY2018 · CA · contact PI